Locus Cell Co Ltd 06891
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- TWD 28.35
- Day Range
- TWD 28.10–28.50
- 52-Week Range
- TWD 22.20–37.20
- Bid/Ask
- TWD 27.95 / TWD 28.20
- Market Cap
- TWD 5.64 Bil
- Volume/Avg
- 14,257 / 260,740
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5,531.71
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Locus Cell Co Ltd focuses on contract development and manufacturing services for cell therapy-related products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 33
- Website
- http://www.locus-cell.com
Comparables
Valuation
|
Metric
|
06891
|
6838
|
6875
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 186.33 |
Price/Book Value | 3.19 | 5.82 | 4.08 |
Price/Sales | 5,531.71 | 44.07 | 24.75 |
Price/Cash Flow | — | — | 163.58 |
Price/Earnings
06891
6838
6875
Financial Strength
|
Metric
|
06891
|
6838
|
6875
|
|---|---|---|---|
Quick Ratio | 16.22 | 6.43 | 15.76 |
Current Ratio | 16.50 | 6.67 | 16.29 |
Interest Coverage | −111.98 | −67.16 | 2.94 |
Quick Ratio
06891
6838
6875
Profitability
|
Metric
|
06891
|
6838
|
6875
|
|---|---|---|---|
Return on Assets (Normalized) | −5.13% | −15.94% | 1.97% |
Return on Equity (Normalized) | −5.43% | −23.61% | 2.23% |
Return on Invested Capital (Normalized) | −6.90% | −23.87% | 0.90% |
Return on Assets
06891
6838
6875
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Qbnqdfkx | Dkfj | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nrqydzxxk | Vccwhs | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gvsjktxp | Dbrdpn | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fvplcqnd | Rtsxtp | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Hxyxyspd | Bzl | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Ltsflhhjn | Gwgvz | $28.1 Bil | |||
| Moderna Inc
MRNA
| Rqqdwgby | Bhmnd | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Zqmbzvhd | Grr | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Gqbkxcwz | Djbspt | $13.4 Bil | |||
| Incyte Corp
INCY
| Dzpqlvn | Ynylhd | $12.7 Bil |
United States